KTTA: Pasithea Therapeutics Corp. Stock

by  •  • Comments Off on KTTA: Pasithea Therapeutics Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.71
Enterprise Value ($M) -3.22
Book Value ($M) 14.78
Book Value / Share 5.46
Price / Book 0.25
NCAV ($M) 6.09
NCAV / Share 2.25
Price / NCAV 0.61

Profitability (mra)
Return on Invested Capital (ROIC) -0.94
Return on Assets (ROA) -0.62
Return on Equity (ROE) -0.70

Liquidity (mrq)
Quick Ratio 6.58
Current Ratio 6.58

Balance Sheet (mrq) ($M)
Current Assets 7.37
Assets 16.06
Liabilities 1.28
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -14.25
Net Income -13.90

Cash Flow Statement (mra) ($M)
Cash From Operations -13.92
Cash from Investing 0.00
Cash from Financing 4.52

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-06 13D/A Steinman Lawrence 3.10 -94.68
02-14 13G/A Armistice Capital, Llc 9.99 15.45

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-24 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 30,507 104,850 29.10
2025-04-16 110,387 278,767 39.60
2025-04-15 86,361 313,073 27.58
2025-04-14 115,565 565,378 20.44

(click for more detail)

Similar Companies
KALA – KALA BIO, Inc. KPRX – Kiora Pharmaceuticals, Inc.
KRRO – Korro Bio, Inc. KZR – Kezar Life Sciences, Inc.
LEXX – Lexaria Bioscience Corp.


Financial data and stock pages provided by
Fintel.io